Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Depreciation & Amortization (2018 - 2021)

Historic Accumulated Depreciation & Amortization for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $246000.0.

  • Black Diamond Therapeutics' Accumulated Depreciation & Amortization rose 6510.07% to $246000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $246000.0, marking a year-over-year increase of 6510.07%. This contributed to the annual value of $164000.0 for FY2020, which is 4642.86% up from last year.
  • According to the latest figures from Q3 2021, Black Diamond Therapeutics' Accumulated Depreciation & Amortization is $246000.0, which was up 6510.07% from $203000.0 recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Accumulated Depreciation & Amortization registered a high of $246000.0 during Q3 2021, and its lowest value of $100000.0 during Q4 2018.
  • Its 4-year average for Accumulated Depreciation & Amortization is $157111.1, with a median of $149000.0 in 2020.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Accumulated Depreciation & Amortization surged by 1200.0% in 2019, and later soared by 6510.07% in 2021.
  • Over the past 4 years, Black Diamond Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $100000.0 in 2018, then increased by 12.0% to $112000.0 in 2019, then surged by 46.43% to $164000.0 in 2020, then skyrocketed by 50.0% to $246000.0 in 2021.
  • Its Accumulated Depreciation & Amortization was $246000.0 in Q3 2021, compared to $203000.0 in Q2 2021 and $183000.0 in Q1 2021.